Recursion, a drug discovery startup out of Salt Lake City, Utah has announced a $60 million Series B round, led by Data Collective (DCVC). Recursion started out in 2014 on a mission to identify ...

Recursion Pharmaceuticals, Inc. With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio ...

Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data Growing interest in AI-powered drug discovery draws some big investors–and regulatory questions ...

Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data Access to Helix’s large-scale clinico-genomic data to drive creation and training of AI models ...